FY26 revenue guidance represents 20%-25% growth compared to the company’s prior year revenue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Is TMDX a Buy, Before Earnings?
- TransMedics: Strong January Transplant Activity Signals Upside to Consensus and Supports Buy Rating
- TransMedics: Robust Early 2026 Demand and DCD Leadership Underpin Buy Rating and Revenue Growth Outlook
- TransMedics receives FDA IDE approval for OCS ENHANCE Heart trial
- TransMedics management to meet virtually with Seaport Research